Literature DB >> 22112481

Molecular pathogenesis of endometrial and ovarian cancer.

Melissa A Merritt1, Daniel W Cramer.   

Abstract

Pregnancy, breastfeeding, and oral contraceptive pill use interrupt menstrual cycles and reduce endometrial and ovarian cancer risk. This suggests the importance of turnover within Mullerian tissues, where the accumulation of mutations in p53 and PTEN has been correlated with number of cycles. The most common type of endometrial cancer (Type I) is endometrioid and molecular abnormalities include mutations in PTEN, KRAS and β-catenin. The Type I precursor is Endometrial Intraepithelial Neoplasia which displays PTEN defects. Type II endometrial cancer (whose precursors are less clear) includes serous and clear cell tumors and the most common alteration is p53 mutation. For ovarian cancer, histopathologic types parallel endometrial cancer and include serous, mucinous, endometrioid, and clear cell; some molecular features are also shared. The most frequent type of ovarian cancer is high grade serous that often displays p53 mutation and its precursor lesions may originate from normal-appearing fallopian tube epithelium that contains a p53 "signature". Mutations in KRAS, BRAF and PTEN are described in mucinous, endometrioid and low grade serous cancers and these may originate from ovarian cortical inclusion cysts. A consideration of molecular and other pathogenetic features, like epidemiology and histopathology, may provide a better understanding of endometrial and ovarian cancer.

Entities:  

Mesh:

Year:  2010        PMID: 22112481      PMCID: PMC3822435          DOI: 10.3233/CBM-2011-0167

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  188 in total

1.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.

Authors:  C Rodriguez; A V Patel; E E Calle; E J Jacob; M J Thun
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

Review 2.  Regulation of p53 function.

Authors:  D B Woods; K H Vousden
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

3.  Lactation and risk of endometrial cancer in Japan: a case-control study.

Authors:  Chikako Okamura; Yoshitaka Tsubono; Kiyoshi Ito; Hitoshi Niikura; Tadao Takano; Satoru Nagase; Kohsuke Yoshinaga; Yukihiro Terada; Takashi Murakami; Shinji Sato; Daisuke Aoki; Toshiko Jobo; Kunihiro Okamura; Nobuo Yaegashi
Journal:  Tohoku J Exp Med       Date:  2006-02       Impact factor: 1.848

4.  Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation.

Authors:  D T Wheeler; K A Bell; R J Kurman; M E Sherman
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

5.  PTEN/MMAC1 mutations in endometrial cancers.

Authors:  J I Risinger; A K Hayes; A Berchuck; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

6.  Evaluation of germline PTEN mutations in endometrial cancer patients.

Authors:  Destin Black; Faina Bogomolniy; Mark E Robson; Kenneth Offit; Richard R Barakat; Jeff Boyd
Journal:  Gynecol Oncol       Date:  2005-01       Impact factor: 5.482

7.  HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.

Authors:  Carl Morrison; Vanna Zanagnolo; Nilsa Ramirez; David E Cohn; Nicole Kelbick; Larry Copeland; G Larry Maxwell; Larry G Maxwell; Jeffrey M Fowler
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

Review 8.  The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system.

Authors:  Jan P Baak; George L Mutter; Stanley Robboy; Paul J van Diest; Anne M Uyterlinde; Anne Orbo; Juan Palazzo; Bent Fiane; Kjell Løvslett; Curt Burger; Feja Voorhorst; René H Verheijen
Journal:  Cancer       Date:  2005-06-01       Impact factor: 6.860

Review 9.  WNT and beta-catenin signalling: diseases and therapies.

Authors:  Randall T Moon; Aimee D Kohn; Giancarlo V De Ferrari; Ajamete Kaykas
Journal:  Nat Rev Genet       Date:  2004-09       Impact factor: 53.242

10.  Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.

Authors:  S C Mok; D A Bell; R C Knapp; P M Fishbaugh; W R Welch; M G Muto; R S Berkowitz; S W Tsao
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

View more
  30 in total

1.  Endometrial Cancer: Comparison of Patients with Synchronous Primary Carcinoma of the Endometrium and Ovary vs. Endometrial Carcinoma with Ovarian Metastases.

Authors:  I Juhasz-Böss; T Fehm; S Becker; R Rothmund; B Krämer; A Staebler; D Wallwiener; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-08-16       Impact factor: 2.915

2.  Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells.

Authors:  Melanie M Scully; Leslie K Palacios-Helgeson; Lah S Wah; Twila A Jackson
Journal:  Horm Cancer       Date:  2014-05-21       Impact factor: 3.869

3.  Post-transcriptional Regulation of MMP16 and TIMP2 Expression via miR-382, miR-410 and miR-200b in Endometrial Cancer.

Authors:  Beata Rak; Dawid Mehlich; Filip Garbicz; Zofia Domosud; Wiktor Paskal; Janina M Marczewska; Paweł K Włodarski
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

4.  The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer.

Authors:  Hiroshi Kobayashi; Kana Iwai; Emiko Niiro; Sachiko Morioka; Yuki Yamada; Kenji Ogawa; Naoki Kawahara
Journal:  Biomed Rep       Date:  2017-07-27

Review 5.  Ovarian cancer : making its own rules-again.

Authors:  Elise C Kohn; Jean Hurteau
Journal:  Cancer       Date:  2012-12-11       Impact factor: 6.860

6.  Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.

Authors:  Helena Schock; Heljä-Marja Surcel; Anne Zeleniuch-Jacquotte; Kjell Grankvist; Hans-Åke Lakso; Renée Turzanski Fortner; Rudolf Kaaks; Eero Pukkala; Matti Lehtinen; Paolo Toniolo; Eva Lundin
Journal:  Endocr Relat Cancer       Date:  2014       Impact factor: 5.678

7.  Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.

Authors:  Moito Iijima; Kouji Banno; Ryuichiro Okawa; Megumi Yanokura; Miho Iida; Takashi Takeda; Haruko Kunitomi-Irie; Masataka Adachi; Kanako Nakamura; Kiyoko Umene; Yuya Nogami; Kenta Masuda; Eiichiro Tominaga; Daisuke Aoki
Journal:  Oncol Lett       Date:  2017-01-10       Impact factor: 2.967

8.  Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.

Authors:  G Pentheroudakis; E A Kotteas; V Kotoula; K Papadopoulou; E Charalambous; A Cervantes; T Ciuleanu; G Fountzilas; N Pavlidis
Journal:  Clin Exp Metastasis       Date:  2014-07-05       Impact factor: 5.150

9.  Reproductive characteristics in relation to ovarian cancer risk by histologic pathways.

Authors:  M A Merritt; M De Pari; A F Vitonis; L J Titus; D W Cramer; K L Terry
Journal:  Hum Reprod       Date:  2013-01-12       Impact factor: 6.918

10.  TC-1 (C8orf4) expression is correlated with differentiation in ovarian carcinomas and might distinguish metastatic ovarian from metastatic colorectal carcinomas.

Authors:  Hong-Tao Xu; Yang Liu; Shu-Li Liu; Yuan Miao; Qing-Chang Li; En-Hua Wang
Journal:  Virchows Arch       Date:  2013-02-02       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.